Literature DB >> 27156708

Risk factors associated with high linezolid trough plasma concentrations.

L Morata1, C De la Calle1, J M Gómez-Cerquera1, L Manzanedo1, G Casals2, M Brunet2, N Cobos-Trigueros1, J A Martínez1, J Mensa1, A Soriano1.   

Abstract

AIM: The major concern of linezolid is the adverse events. High linezolid trough serum concentration (Cmin) has been associated with toxicity. The aim of this study was to analyze factors associated with high Cmin.
METHODS: Main clinical characteristics of 104 patients treated with 600 mg/12 hours of linezolid were retrospectively reviewed. Samples were obtained just before the next dose after at least three doses and within the first 8 days of treatment. High Cmin was considered when it was >8 mg/L. Univariate and multivariate analysis were performed.
RESULTS: 34.6% patients had a Cmin >8 mg/L, and they were older and had more frequently an estimated glomerular filtration by MDRD <40 mL/min. There were more patients co-treated with rifampin in the group with low Cmin. The only factor independently associated with Cmin >8 was the renal function. Patients with an eGF < 40 mL/min had significantly higher Cmin than those with eGF > 80 mL/min (OR: 4.273) and there was a trend towards a high Cmin in patients with eGF between 40-80 mL/min (OR: 2.109).
CONCLUSIONS: High Cmin were frequent, especially in patients with MDRD <40 mL/min. Therapeutic drug monitoring could be useful to avoid toxicity in patients with renal dysfunction.

Entities:  

Keywords:  Glomerular filtration; linezolid; therapeutic drug monitoring; toxicity

Mesh:

Substances:

Year:  2016        PMID: 27156708     DOI: 10.1080/14656566.2016.1182154

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  13 in total

1.  Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety.

Authors:  Ryan L Crass; Pier Giorgio Cojutti; Manjunath P Pai; Federico Pea
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Safety and Tolerability of More than Six Days of Tedizolid Treatment.

Authors:  Mireia Mensa Vendrell; Maria Tasias Pitarch; Miguel Salavert Lletí; Eva Calabuig Muñoz; Laura Morata Ruiz; Genís Castells Lao; Ester López Suñé; Jose Mensa Pueyo; Maria Rosa Oltra Sempere; Maria-Luisa Pedro-Botet Montoya; Valentina Isernia; Esteban Alberto Reynaga Sosa; Leonor Moreno Nuñez; Juan Pasquau Liaño; Sergio Sequera Arquelladas; José Ramón Yuste Ara; Alex Soriano Viladomiu
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 3.  A Review of Population Pharmacokinetic Analyses of Linezolid.

Authors:  Enrique Bandín-Vilar; Laura García-Quintanilla; Ana Castro-Balado; Irene Zarra-Ferro; Miguel González-Barcia; Manuel Campos-Toimil; Víctor Mangas-Sanjuan; Cristina Mondelo-García; Anxo Fernández-Ferreiro
Journal:  Clin Pharmacokinet       Date:  2022-06-14       Impact factor: 5.577

4.  Dosage Strategy of Linezolid According to the Trough Concentration Target and Renal Function in Chinese Critically Ill Patients.

Authors:  Fan Wu; Xiao-Shan Zhang; Ying Dai; Zi-Ye Zhou; Chun-Hong Zhang; Lu Han; Fang-Min Xu; Ye-Xuan Wang; Da-Wei Shi; Guan-Yang Lin; Xu-Ben Yu; Fang Chen
Journal:  Front Pharmacol       Date:  2022-04-11       Impact factor: 5.988

5.  Initially Reduced Linezolid Dosing Regimen to Prevent Thrombocytopenia in Hemodialysis Patients.

Authors:  Hitoshi Kawasuji; Yasuhiro Tsuji; Chika Ogami; Makito Kaneda; Yushi Murai; Kou Kimoto; Akitoshi Ueno; Yuki Miyajima; Yasutaka Fukui; Ippei Sakamaki; Yoshihiro Yamamoto
Journal:  Antibiotics (Basel)       Date:  2021-04-26

6.  Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients.

Authors:  Hitoshi Kawasuji; Yasuhiro Tsuji; Chika Ogami; Kou Kimoto; Akitoshi Ueno; Yuki Miyajima; Koyomi Kawago; Ippei Sakamaki; Yoshihiro Yamamoto
Journal:  BMC Pharmacol Toxicol       Date:  2021-03-04       Impact factor: 2.483

7.  Successful treatment of linezolid-induced severe lactic acidosis with continuous venovenous hemodiafiltration: A case report.

Authors:  Naiju Zhang; Fan Zhang; Zhong Chen; Rui Huang; Juan Xia; Jinchun Liu
Journal:  Saudi Pharm J       Date:  2021-12-31       Impact factor: 4.562

8.  A Novel UPLC-MS/MS Assay for the Measurement of Linezolid and its Metabolite PNU-142300 in Human Serum and its Application to Patients With Renal Insufficiency.

Authors:  Yingying Wang; Er-Min Gu; Xiaoxiang Du; Ren-Ai Xu; Guanyang Lin
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

Review 9.  Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: A systematic review and meta-analysis.

Authors:  Changcheng Shi; Junbo Xia; Jian Ye; Yaping Xie; Weizhong Jin; Wei Zhang; Liusheng Wang; Xuping Ding; Nengming Lin; Limin Wang
Journal:  Br J Clin Pharmacol       Date:  2021-10-10       Impact factor: 3.716

10.  Determining therapeutic trough ranges for linezolid.

Authors:  Abdullah Alsultan
Journal:  Saudi Pharm J       Date:  2019-09-25       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.